These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 18721244)

  • 1. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
    Schiff E; Simsek H; Lee WM; Chao YC; Sette H; Janssen HL; Han SH; Goodman Z; Yang J; Brett-Smith H; Tamez R
    Am J Gastroenterol; 2008 Nov; 103(11):2776-83. PubMed ID: 18721244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
    Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
    N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
    Sims KA; Woodland AM
    Pharmacotherapy; 2006 Dec; 26(12):1745-57. PubMed ID: 17125436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
    N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
    Sherman M; Yurdaydin C; Sollano J; Silva M; Liaw YF; Cianciara J; Boron-Kaczmarska A; Martin P; Goodman Z; Colonno R; Cross A; Denisky G; Kreter B; Hindes R;
    Gastroenterology; 2006 Jun; 130(7):2039-49. PubMed ID: 16762627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
    Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
    Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
    Chang TT; Gish RG; Hadziyannis SJ; Cianciara J; Rizzetto M; Schiff ER; Pastore G; Bacon BR; Poynard T; Joshi S; Klesczewski KS; Thiry A; Rose RE; Colonno RJ; Hindes RG;
    Gastroenterology; 2005 Oct; 129(4):1198-209. PubMed ID: 16230074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients.
    Buti M; Morillas RM; Prieto M; Diago M; Pérez J; Solà R; Bonet L; Palau A; Testillano M; García-Samaniego J; Rodríguez M;
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):535-42. PubMed ID: 22382708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
    J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Chang TT; Chao YC; Gorbakov VV; Han KH; Gish RG; de Man R; Cheinquer H; Bessone F; Brett-Smith H; Tamez R
    J Viral Hepat; 2009 Nov; 16(11):784-9. PubMed ID: 19457141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B].
    Calcagno JI; Augustovski F; Gadano A; Souto A; Yuan Y
    Acta Gastroenterol Latinoam; 2008 Dec; 38(4):260-73. PubMed ID: 19157381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
    Chang TT; Liaw YF; Wu SS; Schiff E; Han KH; Lai CL; Safadi R; Lee SS; Halota W; Goodman Z; Chi YC; Zhang H; Hindes R; Iloeje U; Beebe S; Kreter B
    Hepatology; 2010 Sep; 52(3):886-93. PubMed ID: 20683932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entecavir for the treatment of chronic hepatitis B infection.
    Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
    Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
    Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
    J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation.
    Hsu YC; Mo LR; Chang CY; Perng DS; Tseng CH; Lo GH; Tai CM; Lin CW; Hsu CC; Hsu CY; Huang SC; Lin JT
    Antivir Ther; 2012; 17(4):605-12. PubMed ID: 22301517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
    Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT
    Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entecavir: new drug. Chronic hepatitis B: a last resort.
    Prescrire Int; 2007 Oct; 16(91):183-5. PubMed ID: 17926822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.